🔗 Share this article The Global Health Body Issues Concern Over Severe Scarcity of Obesity Injections Fewer than a tenth of people who could benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it issues its inaugural recommendations on the therapies. Considering over a billion individuals worldwide now classified as obese, it is urging increased and just availability to this class of drugs. Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention. "Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and continuous support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and supply-chain constraints are major obstacles to universal availability to the jabs that can assist patients in reducing considerable body mass, notes the agency. Skinny Jab Supply Crisis Even in the present best projected outlook, the production of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation urges countries and companies to widen access, by approaches like voluntary licensing. The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026. The Way Weight-Loss Drugs Operate The injections mimick a biological compound to reduce digestion speed, curb appetite and enhance the sense of being full so people reduce food intake. Patients commonly see weight reduction within a few weeks of commencing the once-weekly jabs. Evidence points to people may regain a significant portion a year later of discontinuing the medication, as their usual appetite come back. To be overweight or obese increases your chance for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Obesity concerns people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
Fewer than a tenth of people who could benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it issues its inaugural recommendations on the therapies. Considering over a billion individuals worldwide now classified as obese, it is urging increased and just availability to this class of drugs. Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention. "Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and continuous support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and supply-chain constraints are major obstacles to universal availability to the jabs that can assist patients in reducing considerable body mass, notes the agency. Skinny Jab Supply Crisis Even in the present best projected outlook, the production of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation urges countries and companies to widen access, by approaches like voluntary licensing. The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026. The Way Weight-Loss Drugs Operate The injections mimick a biological compound to reduce digestion speed, curb appetite and enhance the sense of being full so people reduce food intake. Patients commonly see weight reduction within a few weeks of commencing the once-weekly jabs. Evidence points to people may regain a significant portion a year later of discontinuing the medication, as their usual appetite come back. To be overweight or obese increases your chance for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Obesity concerns people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the health agency.